Evidence map›Paper›PMID 39792303›Full record

ArticleDrug safety2025

Multi-Stakeholder Call to Action for the Future of Vaccine Post-Marketing Monitoring: Proceedings from the First Beyond COVID-19 Monitoring Excellence (BeCOME) Conference.

Vincent Bauchau, Kaatje Bollaerts, Phil Bryan, Jim Buttery, Kourtney Davis, Robert T Chen, Daniel R Feikin, Antonella Fretta, Sarah Frise, Sonja Gandhi-Banga and 19 more

Abstract read
In one paragraph

Article in Drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Vincent BauchauIndependent, Previously GSK, Vaccine Safety, Wavre, Belgium.
Kaatje BollaertsP95 (Epidemiology and Pharmacovigilance Consultant and Services), Leuven (Flemish Brabant), Belgium.
Phil BryanGSK (Safety Evaluation and Risk Management), London, UK.
Jim ButteryMurdoch Childrens Research Institute, University of Melbourne, Melbourne, VIC, Australia.
Kourtney DavisJanssen Research and Development LLC (Global Epidemiology), Horsham, PA, USA.
Robert T ChenBrighton Collaboration (A Program of the Task Force for Global Health), Decatur, GA, USA.
Daniel R FeikinWorld Health Organization, Geneva, Switzerland.
Antonella FrettaPfizer (Worldwide Medical & Safety), New York, NY, USA.
Sarah FriseAstraZeneca (Global Patient Safety), Mississauga, ON, Canada. Sarah.frise@astrazeneca.com.ORCID http://orcid.org/0000-0002-5796-1158
Sonja Gandhi-BangaSanofi (Global Pharmacovigilance), Toronto, ON, Canada.
Hector S IzurietaUS Food and Drug Administration (Center for Biologics Evaluation and Research), Silver Spring, MD, USA.
Corinne Jouquelet-RoyerSanofi (Patient Safety and Pharmacovigilance), Lyon, Auvergne-Rhone-Alpes, France.
Alena KhromavaSanofi (Global Pharmacovigilance), Toronto, ON, Canada.
Lin LiSanofi (Epidemiology and Benefit Risk), Bridgewater, NJ, USA.
Raj LongIndependent, Previously Bill & Melinda Gates Foundation (Safety & Pharmacovigilance), London, UK.
Sarah MacDonaldPfizer (Worldwide Medical & Safety), New York, NY, USA.
Lydie MarcelonSanofi (Epidemiology and Benefit Risk Evaluation), Lyon, Auvergne-Rhone-Aples, France.
Robert MassouhGSK (Safety Evaluation and Risk Management), London, UK.
Wilhelmine MeerausAstraZeneca (Medical Evidence, Vaccines & Immune Therapies), Cambridge, UK.
Flor M MunozDepartment of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
Karen NaimPfizer (Worldwide Medical & Safety), New York, NY, USA.
Dale NordenbergThriive.AI, Bronx, NY, USA.
Hanna NohynekNational Institute for Health and Welfare (Infectious Diseases Control and Vaccines), Helsinki, Finland.
Heather RubinoPfizer (Worldwide Medical & Safety), New York, NY, USA.
Daniel A SalmonSchool of Public Health (Department of International Health, Institute for Vaccine Safety), Johns Hopkins Bloomberg, Baltimore, MD, USA.
Sarah SellersNovavax (Safety Science and Surveillance), Gaithersburg, MD, USA.
Laurence SerradellSanofi (Epidemiology and Benefit Risk Evaluation), Lyon, Auvergne-Rhone-Aples, France.
Laurence Torcel-PagnonSanofi (Vaccines Medical Global Evidence Generation Influenza), Lyon, Auvergne-Rhone-Alpes, France.
Jamie WilkinsPfizer (Worldwide Medical & Safety), New York, NY, USA.

Funding

World Health Organization 001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39792303
PMCPMC11982078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.